Body fat reduction market seen topping $22.9 billion by 2030

The global body fat reduction market is forecast to grow at a 10% annual pace and surpass $22.93 billion by 2030, according to The Business Research Company. Asia-Pacific is expected to become the largest regional market, while the U.S. remains the biggest national market.

Why it matters: - The body fat reduction market is gaining from rising demand for aesthetic wellness, minimally invasive procedures and technology-driven contouring treatments. - The market’s projected growth points to continued spending on cosmetic services despite broader healthcare pressures. - The category sits within a much larger healthcare services market, but remains a small share of the total.

What happened: - The Business Research Company released its Body Fat Reduction Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the global body fat reduction market is expected to exceed $22.93 billion by 2030. - The market is projected to grow at a 10% compound annual growth rate through 2030. - Asia-Pacific is expected to become the largest regional market by 2030, reaching $8 billion from $4 billion in 2025. - The U.S. is projected to remain the largest country market by 2030 at $7 billion, up from $5 billion in 2025.

The details: - The report estimates body fat reduction will account for about 0.5% of the projected $4,896 billion hospitals market in 2030. - The category will represent close to 0.2% of the projected $11,335 billion healthcare services market in 2030. - Surgical procedures are expected to dominate in 2030 with 89% of the market, or about $20 billion. - Non-surgical methods including cryolipolysis, laser-assisted therapy, ultrasound, radiofrequency and high-intensity focused electromagnetic therapy are gaining share because they offer less discomfort, quicker recovery and lower risk. - The market is split by gender into male and female segments and by service provider into medical spas, hospitals and clinics. - AbbVie Inc. held the top global position in 2025 with a 3% market share. - InMode Ltd. and BTL Industries each held 2% market share in 2025. - The top 10 companies accounted for just 7% of total revenue in 2025, underscoring a fragmented market. - Other named competitors include Candela Medical, Cynosure, Lumenis, Solta Medical, Cutera, Sciton, Jeisys Medical, Erchonia, Fosun Pharmaceuticals, Apollo Hospitals, Sono Bello, Ideal Image, LaserAway, AirSculpt Technologies, VLCC Health Care and VIDA Wellness and Beauty. - The report points to supply-chain participants including AbbVie, Merz Pharma, Galderma, Sinclair Pharma, Teoxane, Revance Therapeutics and Ipsen, along with distributors such as McKesson, Cardinal Health, Henry Schein, Medline, Owens & Minor and Cencora. - End users include major medical device and aesthetic companies such as Johnson & Johnson MedTech, Boston Scientific, Medtronic, Stryker, Olympus, Hologic, BTL Industries, Syneron Medical, Apyx Medical, Invasix Aesthetic Solutions, Ideal Image Development, Sono Bello and specialized clinics worldwide. - The report’s market package includes attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics, future trend analysis and updated graphics and tables.

Between the lines: - The market remains fragmented because innovation cycles are fast and providers need to differentiate on safety, efficacy and personalization. - Consumer demand is being shaped by obesity concerns, social media, fitness culture and higher disposable incomes. - The strongest growth appears to be coming from consumers who want contouring results with less downtime and less invasive care. - The report highlights AI as an emerging tool for treatment planning and monitoring, suggesting competition may increasingly shift toward software-enabled precision and personalization. - BTL Aesthetics launched EXION in January 2024, combining radiofrequency with targeted ultrasound in a needle-free applicator for aesthetic use.

What's next: - Asia-Pacific is expected to keep widening its lead as clinics expand in urban areas and access to advanced sculpting treatments improves. - The U.S. market is likely to stay dominant as demand for minimally invasive cosmetic procedures and device innovation continues. - Companies are expected to keep investing in non-surgical technologies, personalized protocols and AI-supported treatment planning. - Partnerships with dermatology clinics, medical spas and cosmetic surgery centers are likely to remain a key route to distribution and growth.

The bottom line: - Body fat reduction is moving from a niche aesthetic category to a larger, technology-led market with broad global growth, but competition remains highly fragmented.